Richard G. Stock, MD, presented “Adjuvant-Salvage Radiotherapy Following Prostatectomy” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 14, 2023, in Scottsdale, Arizona.
How to cite: Stock, Richard G. “Adjuvant-Salvage Radiotherapy Following Prostatectomy.” April 14, 2023. Accessed Nov 2025. https://grandroundsinurology.com/adjuvant-salvage-radiotherapy-following-prostatectomy/
Adjuvant-Salvage Radiotherapy Following Prostatectomy – Summary
Richard G. Stock, MD analyzes adjuvant and salvage radiotherapy following prostatectomy in prostate cancer patients with high-risk features or biochemical recurrence post-surgery. Adjuvant radiotherapy is administered shortly after prostatectomy in patients with adverse pathological features, such as positive surgical margins or seminal vesicle invasion, aiming to eradicate microscopic residual disease. Salvage radiotherapy is employed in response to a rising prostate-specific antigen (PSA) level indicating biochemical recurrence after an initial period of undetectable PSA post-surgery.
Dr. Stock reviews pivotal clinical trials and studies, including the SWOG 8794, EORTC 22911, and ARO 96-02 trials, which have demonstrated the efficacy of adjuvant radiotherapy in improving biochemical progression-free survival and overall survival in patients with high-risk features. He highlights the long-term benefits of early intervention with radiotherapy, emphasizing its potential to prevent metastatic progression.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.
